Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The Center for Excellence in Aging and Geriatric Health
mi
from
Williamsburg, VA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The Center for Excellence in Aging and Geriatric Health
mi
from
Williamsburg, VA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Clinical Site 1
mi
from
Bucharest,
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Clinical Site 1
mi
from
Bucharest,
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Summit, NJ
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Summit, NJ
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
St. Petersburg, FL
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Marlton, NJ
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Manhasset, NY
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
New York, NY
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Cincinnati, OH
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Orem, UT
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Orange, CA
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Brockton, MA
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Brockton, MA
Click here to add this to my saved trials
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Natick, MA
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Natick, MA
Click here to add this to my saved trials
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Watertown, MA
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Watertown, MA
Click here to add this to my saved trials
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Intergrated Medical and Behavioral Associates
mi
from
Glendale, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Intergrated Medical and Behavioral Associates
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Excell Research, Inc.
mi
from
Oceanside, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Excell Research, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
University of California, San Diego
mi
from
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Affiliated Research Institute
mi
from
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Affiliated Research Institute
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Scientific Clinical Research
mi
from
North Miami, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Scientific Clinical Research
mi
from
North Miami, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Uptown Research Institute, Llc
mi
from
Chicago, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Uptown Research Institute, Llc
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Alexian Brothers Behavioral Health
mi
from
Hoffman Estates, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Alexian Brothers Behavioral Health
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CBH Health LLC
mi
from
Rockville, MD
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CBH Health LLC
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Carolina Clinical Trials, Inc.
mi
from
Charleston, SC
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Carolina Clinical Trials, Inc.
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Vanderbilt Psychiatric Hospital
mi
from
Nashville, TN
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Vanderbilt Psychiatric Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
InSite Clinical Research LLC
mi
from
DeSoto, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
InSite Clinical Research LLC
mi
from
DeSoto, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
mi
from
Arkhangelsk,
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
mi
from
Arkhangelsk,
Click here to add this to my saved trials
Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine
Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine
Status: Enrolling
Updated:  4/1/2014
Neurology Group of Bergen County
mi
from
Ridgewood, NJ
Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine
Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine
Status: Enrolling
Updated: 4/1/2014
Neurology Group of Bergen County
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Brain Injury
A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Severe Traumatic Brain Injury
Status: Enrolling
Updated:  4/4/2014
Parkland Hospital
mi
from
Dallas, TX
Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Brain Injury
A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Severe Traumatic Brain Injury
Status: Enrolling
Updated: 4/4/2014
Parkland Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Brain Injury
A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Severe Traumatic Brain Injury
Status: Enrolling
Updated:  4/4/2014
Baylor University Medical Center
mi
from
Dallas, TX
Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Brain Injury
A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Severe Traumatic Brain Injury
Status: Enrolling
Updated: 4/4/2014
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities
Targeted Lower Extremity Joint Training Effects on MS Gait Abnormalities
Status: Enrolling
Updated:  4/7/2014
Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital
mi
from
Hartford, CT
Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities
Targeted Lower Extremity Joint Training Effects on MS Gait Abnormalities
Status: Enrolling
Updated: 4/7/2014
Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Cerritos, CA
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Cerritos, CA
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Garden Grove, CA
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Long Beach, CA
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
National City, CA
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Oceanside, CA
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
San Diego, CA
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Washington,
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Atlanta, GA
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
St Louis, MO
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Marlton, NJ
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Dayton, OH
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated:  4/9/2014
Clinical Research Facility
mi
from
Irving, TX
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole
Status: Enrolling
Updated: 4/9/2014
Clinical Research Facility
mi
from
Irving, TX
Click here to add this to my saved trials
Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity
ASSESSMENT OF A POTASSIUM OXALATE CONTAINING FORMULATION FOR THE RELIEF OF DENTINAL HYPERSENSITIVITY
Status: Enrolling
Updated:  4/10/2014
Salus Research, Inc.
mi
from
Fort Wayne, IN
Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity
ASSESSMENT OF A POTASSIUM OXALATE CONTAINING FORMULATION FOR THE RELIEF OF DENTINAL HYPERSENSITIVITY
Status: Enrolling
Updated: 4/10/2014
Salus Research, Inc.
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity
ASSESSMENT OF A POTASSIUM OXALATE CONTAINING FORMULATION FOR THE RELIEF OF DENTINAL HYPERSENSITIVITY
Status: Enrolling
Updated:  4/10/2014
Silverstone
mi
from
Las Vegas, NV
Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity
ASSESSMENT OF A POTASSIUM OXALATE CONTAINING FORMULATION FOR THE RELIEF OF DENTINAL HYPERSENSITIVITY
Status: Enrolling
Updated: 4/10/2014
Silverstone
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism
A Randomized Double-Blind Sham-Controlled Trial To Evaluate The Treatment Efficacy of Magnetic Resonant Therapy in Autistic Disorder
Status: Enrolling
Updated:  4/15/2014
Brain Treatment Center
mi
from
Newport Beach, CA
A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism
A Randomized Double-Blind Sham-Controlled Trial To Evaluate The Treatment Efficacy of Magnetic Resonant Therapy in Autistic Disorder
Status: Enrolling
Updated: 4/15/2014
Brain Treatment Center
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism
A Randomized Double-Blind Sham-Controlled Trial To Evaluate The Treatment Efficacy of Magnetic Resonant Therapy in Autistic Disorder
Status: Enrolling
Updated:  4/15/2014
Brain Treatment Center of Atlanta
mi
from
Buford, GA
A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism
A Randomized Double-Blind Sham-Controlled Trial To Evaluate The Treatment Efficacy of Magnetic Resonant Therapy in Autistic Disorder
Status: Enrolling
Updated: 4/15/2014
Brain Treatment Center of Atlanta
mi
from
Buford, GA
Click here to add this to my saved trials